Amgen Fourth-Quarter Earnings Rise on Higher Drug Sales
This article is for subscribers only.
Amgen Inc., the world’s largest biotechnology company by revenue, reported fourth-quarter earnings rose 30 percent on higher sales of medicines including Neulasta and Prolia.
Net income increased to $1.02 billion, or $1.33 a share, from $788 million, or $1.01, a year earlier, the Thousand Oaks, California-based company said today in a statement. Adjusted for one-time items, profit was $1.82 a share, beating the $1.69 average of 21 analysts’ estimates compiled by Bloomberg. Quarterly revenue gained 13 percent to $5.01 billion.